Clinical trials · Boston, MA
Refractory Acute Myeloid Leukemia clinical trials in Boston
We’re tracking 30 recruiting refractory acute myeloid leukemia studies with a site in or near Boston — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 2/Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT06707493RecruitingPhase 2
Ivosidenib after stem cell transplant for IDH1-mutated AML
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
Boston, MassachusettsAges 18–75 - NCT06376162RecruitingPhase 1
Ziftomenib with chemo for kids with relapsed acute leukemia
This trial tests a new targeted drug called ziftomenib combined with chemotherapy for children whose leukemia (with specific genetic changes) has come back or is not responding to treatment. The goal is to see if this combination can help control the cancer.
Boston, MassachusettsAges birth–21 years - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Boston, MassachusettsAges 1–18 - NCT04811560RecruitingPhase 1/Phase 2
Study of a targeted medicine for certain relapsed leukemia
This Phase 1/2 trial tests bleximenib, a targeted medicine, for people whose acute leukemia has specific gene changes and has come back or does not respond to treatment. It may help by attacking these leukemia-specific targets when other treatment options have run out.
Boston, MassachusettsAges 2 years+ - NCT06660368RecruitingPhase 2
A study of a drug combo for relapsed or refractory AML
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
Boston, MassachusettsAges 18–80 - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Boston, MassachusettsAges 18 years+ - NCT03595917RecruitingPhase 1
New and hard-to-treat BCR-ABL leukemia drugs plus prednisone and blinatumomab
This Phase 1 study tests a combination of targeted cancer drugs with prednisone and blinatumomab in people with BCR-ABL–positive B-cell leukemia (B-ALL), or chronic myeloid leukemia (CML) in lymphoid blast crisis. It may help by attacking leukemia cells through multiple pathways, especially when standard intensive chemotherapy is not suitable.
Boston, MassachusettsAges 18 years+ - NCT06994676RecruitingPhase 1
Study of CBX-250 for advanced myeloid leukemias
This study tests an experimental drug, CBX-250, for people with certain advanced blood cancers (like AML) that have not responded to standard treatments or have returned. The drug works only for people who have a specific genetic marker (HLA-A*02:01). The goal is to see if it is safe and how well it works.
Boston, MassachusettsAges 12 years+ - NCT03471260RecruitingPhase 1/Phase 2
Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT07439211RecruitingPhase 1
Testing a new drug combo for acute myeloid leukemia
This trial tests a new drug, eganelisib, combined with azacitidine and venetoclax for patients with acute myeloid leukemia (AML). It's for people whose AML has come back or hasn't responded to treatment, or for those with a high-risk type who haven't been treated yet.
Boston, MassachusettsAges 18–90 - NCT04256317RecruitingPhase 2/Phase 3
Azacitidine pills with or without venetoclax for certain blood cancers
This study tests whether a pill form of azacitidine (ASTX030) helps people with myelodysplastic syndromes (MDS), CMML, or AML. Some groups may also receive venetoclax; the goal is better blood cancer control for people who aren’t good candidates for intensive chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT05703542RecruitingPhase 1
Testing BXCL701 for relapsed or resistant AML or MDS
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
Boston, MassachusettsAges 18 years+ - NCT06297941RecruitingPhase 1
Study of REM-422 for AML or high-risk MDS
This trial tests an experimental oral medication called REM-422 for people with AML (a type of blood cancer) that has not responded to treatment or has come back, or for those with high-risk MDS. The goal is to see if it is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Boston, MassachusettsAges 1–21 - NCT06419634RecruitingPhase 1
New drug combo for returning AML or MDS
This study tests a new drug (BMS-986497) alone or combined with two other medicines (azacitidine and venetoclax) for people with AML or MDS that has not responded to or returned after prior treatments. The goal is to see if this combination can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT04227847RecruitingPhase 1
Study of a CD70-targeting drug for blood cancer
This Phase 1 study tests the safety of SEA-CD70, a drug that targets CD70, in people with certain blood cancers like MDS and AML. It may help doctors learn whether this approach can be used safely for patients whose disease has come back or not responded to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06950034RecruitingPhase 1
Testing STX-0712 for advanced CMML or AML
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
Boston, MassachusettsAges 18 years+ - NCT06472128Recruiting
New digital app for adults with acute myeloid leukemia
This study tests a digital application to help patients with acute myeloid leukemia (AML) during their hospital stay. It may assist with tracking symptoms, education, or communication with care teams.
Boston, MassachusettsAges 18–120 - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
Boston, MassachusettsAges 18 years+ - NCT03113643RecruitingPhase 1
SL-401 with standard drugs for hard-to-treat blood cancers
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
Boston, MassachusettsAges 18 years+ - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
Boston, MassachusettsAges 18 years+ - NCT05237258Recruiting
Compare palliative care approaches for people with high-risk AML
This study tests a specialized (targeted) palliative care program versus usual oncology care for people hospitalized with high-risk acute myeloid leukemia (AML). The goal is to see if this palliative approach improves comfort, support, and care planning during intensive treatment.
Boston, MassachusettsAges 18–120 - NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Boston, MassachusettsAges 13 years+ - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Boston, MassachusettsAges Up to 22 years
Hear when a new Refractory Acute Myeloid Leukemia trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Refractory Acute Myeloid Leukemia trials in other cities
Where these studies are running near Boston
Institutions with a site for the recruiting refractory acute myeloid leukemia studies listed above.
- Dana-Farber Cancer Institute · 19 studies
- Massachusetts General Hospital · 9 studies
- Beth Israel Deaconess Medical Center · 2 studies
- Brigham and Women's Hospital
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center
- Local Institution - 0007
- Maine Health
- Rhode Island Hospital
What taking part in a refractory acute myeloid leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting refractory acute myeloid leukemia studies in Massachusetts.
Common questions
- Are there refractory acute myeloid leukemia clinical trials near Boston?
- Yes. We're currently tracking 30 recruiting refractory acute myeloid leukemia studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a refractory acute myeloid leukemia study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a refractory acute myeloid leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New refractory acute myeloid leukemia studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.